Quest Diagnostics Incorporated (DGX) News
Follow Quest Diagnostics Incorporated (DGX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 58 public stories across 26 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Quest Diagnostics Pays About $13 Million to Settle Kickback Allegations
Quest Diagnostics paid about $13 million to the Justice Department to settle allegations that it offered healthcare providers and executives illegal kickbacks to generate business referrals.
REGULATION | Nov 06, 2026, 10:47 PM UTC
M
Quest Diagnostics Reports Third-Quarter Revenue of $3.1B, EPS of $2.78
Quest Diagnostics reported third-quarter 2026 net income of $312 million. Revenue, net income and diluted EPS rose 10%, 27.3% and 28.7%, respectively, from the prior-year quarter.
EQUITY | Oct 23, 2026, 08:21 PM UTC
M
Quest Diagnostics Reports Quarterly Results for Period Ended Sept. 30
EQUITY | Oct 22, 2026, 01:32 PM UTC
M
Quest Diagnostics Reports Cyber Breach Affecting Patient Records
Quest Diagnostics said it learned of unauthorized access to its Quanum LSM system, used by some clients to place test orders and access results.
EQUITY | Oct 22, 2026, 11:38 AM UTC
M
Quest Diagnostics Reports Q3 Results and Raises 2026 Guidance
Quest Diagnostics reported adjusted EPS of $3.00 and revenue of $3.10 billion, above FactSet estimates of $2.87 and $3.05 billion, respectively. It raised its 2026 revenue guidance to $12.07 billion-$12.11 billion and ad
EQUITY | Oct 22, 2026, 11:33 AM UTC
M
Quest Diagnostics Sees 2026 Adjusted EPS of $11.05-$11.25
EARNINGS | Oct 22, 2026, 11:16 AM UTC
M
Quest Diagnostics Sees FY Revenue of $12.07B-$12.11B
EARNINGS | Oct 22, 2026, 10:55 AM UTC
L
Quest Diagnostics Reports Third-Quarter Adjusted EPS of $3.00
EARNINGS | Oct 22, 2026, 10:53 AM UTC
M
Quest Diagnostics Raises 2026 Cash-Flow View to About $1.9B
Quest Diagnostics raised its 2026 cash provided by operations outlook to about $1.9 billion from about $1.8 billion.
EARNINGS | Oct 22, 2026, 10:48 AM UTC
L
Quest Diagnostics Reports Third-Quarter EPS of $2.78
EARNINGS | Oct 22, 2026, 10:46 AM UTC
M
Quest Diagnostics Sees FY EPS of $10.21–$10.31
EARNINGS | Oct 22, 2026, 10:46 AM UTC
M
Quest Diagnostics reports third-quarter net income of $312 million
EARNINGS | Oct 22, 2026, 10:46 AM UTC
M
Quest Diagnostics Sees FY Adjusted EPS of $11.25-$11.35
EARNINGS | Oct 22, 2026, 10:46 AM UTC
M
Quest Diagnostics Expected to Post $2.86 per Share in Earnings
An earnings preview cites expected earnings of $2.86 per share for Quest Diagnostics.
EQUITY | Oct 20, 2026, 12:38 PM UTC
L
Study finds screening thresholds may miss half of primary aldosteronism patients
A study published in Hypertension finds current screening thresholds may miss half of patients with primary aldosteronism, a leading cause of severe high blood pressure.
EQUITY | Oct 19, 2026, 11:57 AM UTC
M
Quest Diagnostics Q3'26 Revenue Estimate Is 3.05B USD
Quest Diagnostics is scheduled to report Q3'26 results on October 22 before the market opens. Revenue is estimated at 3.05 billion USD and EPS at 2.87 USD.
EQUITY | Oct 15, 2026, 11:00 AM UTC
M
Digi Power X Secures $200M Debt Commitment for Alabama AI Data Center
Digi Power X received a $200 million debt-financing commitment letter for its 40 MW Alabama AI data center. Closing is expected within 90 days, subject to diligence and other conditions; construction remains on schedule,
EQUITY | Oct 13, 2026, 11:36 AM UTC
M
Digi Power X secures $200 million debt financing commitment
The company says the commitment will support completion of its Alabama AI data center and provided an expansion update.
EQUITY | Oct 13, 2026, 11:30 AM UTC
L
DGX - Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
DGX - Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
EARNINGS | Sep 22, 2026, 08:29 PM UTC
M
Diagnostic-testing stocks drop after proposed Medicare lab payment cuts
Labcorp and Quest Diagnostics shares fell in premarket after CMS proposed cuts to Medicare payment rates for laboratory services.
EQUITY | Sep 22, 2026, 01:10 PM UTC
H
Why Vicor Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corp (NASDAQ: VICR ) rose sharply in pre-market trading after the company raised guidance for the third quarter. After the market close on Monday, Vicor raised its third-quarter growth guidance from nearl
LIVE | Sep 22, 2026, 09:30 AM UTC
L
DGX - Nearly 1 in 3 Patients with Suspected Lyme Disease are Co- Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
DGX - Nearly 1 in 3 Patients with Suspected Lyme Disease are Co- Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
NEWS | Sep 21, 2026, 12:03 PM UTC
L
DGX - Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
DGX - Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
NEWS | Sep 16, 2026, 12:03 PM UTC
H
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The U.S. 10-year Treasury yield broke above 5% on Tuesday, and crude oil stormed past $105 a barrel, a combination that left every major U.S. equity index in the red at midday. President Donald Trump said on Truth Social
LIVE | Sep 15, 2026, 05:27 PM UTC
H
DGX: Organic growth, consumer health, and partnerships drive strong results amid regulatory uncertainty
Revenue and earnings growth have outpaced long-range plans, driven by organic expansion, strategic partnerships, and a booming consumer health segment. Integration of major deals and disciplined M&A remain priorities, wh
EARNINGS | Sep 15, 2026, 04:32 PM UTC
H
DGX: Organic growth and consumer health drive strong results, with regulatory advocacy ongoing
Revenue and earnings growth have outpaced long-range plans, driven mainly by organic expansion and strategic partnerships. Consumer health and wellness segments are growing rapidly, supported by stable pricing and high m
EARNINGS | Sep 15, 2026, 04:01 PM UTC
L
DGX - Apple Health app Users to be Able to Order Labs from Quest Diagnostics
DGX - Apple Health app Users to be Able to Order Labs from Quest Diagnostics
EQUITY | Sep 09, 2026, 08:01 PM UTC
M
Quest Diagnostics price target raised to $245 by UBS
UBS raised its price target on Quest Diagnostics to $245.00 per share from $232.00, according to Benzinga ratings actions relayed via TradingView News.
EQUITY | Sep 08, 2026, 05:08 PM UTC
L
Renalytix PLC collaboration with Quest Diagnostics
Renalytix PLC announces a collaboration with Quest Diagnostics.
EQUITY | Sep 01, 2026, 06:01 AM UTC
L
DGX - Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
DGX - Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
EQUITY | Aug 25, 2026, 01:30 PM UTC
L
DGX - Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
DGX - Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
EQUITY | Aug 25, 2026, 12:01 PM UTC
L
Quest Diagnostics to speak at Morgan Stanley Global Healthcare conference
Quest Diagnostics (DGX) will speak at the Morgan Stanley 24th Annual Global Healthcare Conference, according to the announcement.
EQUITY | Aug 24, 2026, 01:01 PM UTC
L
Quest Diagnostics to add Roche ptau217, launch Ad-detect test
Quest Diagnostics says it will incorporate Roche ptau217 testing into Ad-detect panels in 2027 and launch a new Ad-detect multi-biomarker lab test nationwide at month-end.
EQUITY | Aug 24, 2026, 11:29 AM UTC
H
Quest Diagnostics to offer FDA-cleared Roche pTau217 blood test
Quest Diagnostics says it will offer the FDA-cleared Roche pTau217 blood test to assess Alzheimer's disease pathology.
REGULATION | Aug 24, 2026, 11:26 AM UTC
L
DGX - WHOOP Makes Advanced Labs Available Without a Wearable Membership
DGX - WHOOP Makes Advanced Labs Available Without a Wearable Membership
EQUITY | Aug 18, 2026, 01:07 PM UTC
H
Digi Power X reports Q2 2026 results; issues operational update and 2027 outlook
Digi Power X says it reports second quarter 2026 financial results and provides an operational update alongside 2027 outlook.
EARNINGS | Aug 14, 2026, 11:30 AM UTC
L
DGX Declares Quarterly Cash Dividend
Quest Diagnostics declares quarterly cash dividend
EQUITY | Aug 12, 2026, 08:15 PM UTC
H
DGXX DGX DGX - Digi Power X to Announce 2026 Q2 Financial Results and Provide Operations Update on August 14th
DGXX DGX DGX - Digi Power X to Announce 2026 Q2 Financial Results and Provide Operations Update on August 14th
EARNINGS | Aug 04, 2026, 11:30 AM UTC
M
Quest Diagnostics: BV linked to STI co-infection
Quest Diagnostics study finds bacterial vaginosis link
EQUITY | Jul 30, 2026, 11:32 AM UTC
L
Quest Diagnostics price target raised by $20 at BofA, here's why
Quest Diagnostics price target raised by $20 at BofA, here's why
EQUITY | Jul 24, 2026, 02:11 PM UTC
L
AMBP CVS DGX DOW UNP CYH MBLY NVR PKG ROL TMUS PT changes @ UBS
AMBP CVS DGX DOW UNP CYH MBLY NVR PKG ROL TMUS PT changes @ UBS
EQUITY | Jul 24, 2026, 12:34 PM UTC
L
DGX Big beat & raise on organic volume; Utilization healthy, despite debate; Reiterate Buy @ BAML
DGX Big beat & raise on organic volume; Utilization healthy, despite debate; Reiterate Buy @ BAML
EQUITY | Jul 24, 2026, 12:28 PM UTC
H
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning
Quest Diagnostics Incorporated (NYSE: DGX ) stock surged Thursday after the diagnostic testing company reported second-quarter results that topped Wall Street expectations and raised its full-year 2026 guidance. Earnings
EARNINGS | Jul 23, 2026, 05:47 PM UTC
L
Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - WYNN +7.20%, TSCO +6.63%, LVS +5.93%, YUM +4.79%, GRMN +4.78%
Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - WYNN +7.20%, TSCO +6.63%, LVS +5.93%, YUM +4.79%, GRMN +4.78% Consumer Staples (XLP) - CASY +3.38%, MO +1.29%, ADM +1.01%, PEP +0.83%, BG +0.
RATES | Jul 23, 2026, 04:00 PM UTC
H
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index dipping around 450 points on Thursday. Shares of Lockheed Martin Corp (NYSE: LMT ) rose sharply after the company reported better-than-expected second-quarter financial re
EARNINGS | Jul 23, 2026, 02:20 PM UTC
L
DGX +11% after Co forecasts annual revenue, profit above estimates
DGX +11% after Co forecasts annual revenue, profit above estimates
EARNINGS | Jul 23, 2026, 01:34 PM UTC
H
Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call
Quest Diagnostics (NYSE: DGX ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For comprehensiv
EARNINGS | Jul 23, 2026, 01:33 PM UTC
L
DGX Quest Diagnostics exec notes expects Nova expenses in second half to account for about 70% of full-year total, vs prior expectation of 6
DGX Quest Diagnostics exec notes expects Nova expenses in second half to account for about 70% of full-year total, vs prior expectation of 60% - conf call
RATES | Jul 23, 2026, 12:59 PM UTC
H
among early movers from the earnings calendar this morning gainers NVCR +15.6%, CLF +15.3%, AMBP +10.2%, COCO +9.9%, WST +9.6%, ALLE +8.4%,
among early movers from the earnings calendar this morning gainers NVCR +15.6%, CLF +15.3%, AMBP +10.2%, COCO +9.9%, WST +9.6%, ALLE +8.4%, DGX +8.2%, ROP +6.2%, TMO +5.6%, IMAX +5.6%, IBCP +5.5%, RTX +5.3%, LMT +5.3%, H
EARNINGS | Jul 23, 2026, 12:52 PM UTC
L
DGX +7% premarket after results
DGX +7% premarket after results
EQUITY | Jul 23, 2026, 12:14 PM UTC
L
Quest Diagnostics ups FY26 adjusted EPS view to $11.05-$11.25 from $10.63-$10.83
Consensus $10.77. Raises...
EARNINGS | Jul 23, 2026, 10:51 AM UTC
L
Quest Diagnostics reports Q2 adjusted EPS $3.12, consensus $2.82
Reports Q2 revenue...
EQUITY | Jul 23, 2026, 10:49 AM UTC
H
Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 Est
Quest Diagnostics (NYSE: DGX ) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 analyst estimate..
EARNINGS | Jul 23, 2026, 10:46 AM UTC
H
DGX Quest Diagnostics RESULTS: Q2, Q2 REV $3.043B vs. EST $2.967B, Q2 EPS $2.84, Q2 Net Income $320M, Q2 ADJ EPS $3.12 vs. EST $2.83, Quest
DGX Quest Diagnostics RESULTS: Q2, Q2 REV $3.043B vs. EST $2.967B, Q2 EPS $2.84, Q2 Net Income $320M, Q2 ADJ EPS $3.12 vs. EST $2.83, Quest Diagnostics Earnings Notes:, Outlook FY REV $11,950-12.050B vs. EST $11.851B, Ou
RATES | Jul 23, 2026, 10:45 AM UTC
L
Implied EPS movers for tomorrow AM: TMO +/-5.2%, HON +/-4.6%, TMUS +/-4.8%, RTX +/-4.3%, INFY +/-16.4%, CMCSA +/-5.1%, UNP +/-3.7%, TECK +/
Implied EPS movers for tomorrow AM: TMO +/-5.2%, HON +/-4.6%, TMUS +/-4.8%, RTX +/-4.3%, INFY +/-16.4%, CMCSA +/-5.1%, UNP +/-3.7%, TECK +/-4.4%, FCX +/-5.1%, AAL +/-5.8%, LMT +/-4.6%, NDAQ +/-3.7%, BX +/-4.0%, ROP +/-8.
EARNINGS | Jul 22, 2026, 06:29 PM UTC
L
BMY NVDA Bristol Myers buys Nvidia's latest AI Computing system for drug research New York, July 20 (Reuters) - Bristol Myers Squibb (BMY) s
BMY NVDA Bristol Myers buys Nvidia's latest AI Computing system for drug research New York, July 20 (Reuters) - Bristol Myers Squibb (BMY) said on Monday it is buying the latest-generation Computing system from chip comp
EQUITY | Jul 20, 2026, 11:00 AM UTC
M
DGX Gets NY Approval
Quest Diagnostics receives New York's Department of Health's approval for its Haystack Minimal Residual Disease liquid biopsy test
EQUITY | Jun 24, 2026, 12:57 PM UTC
L
DGX - Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease
Quest Diagnostics receives New York State approval for Haystack MRD, broadening patient access to ctDNA minimal residual disease testing
EQUITY | Jun 24, 2026, 12:54 PM UTC